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S UMMA R Y
Existing approaches to tuberculosis (TB) control have
been no more than partially successful in areas with high
human immunodeficiency virus (HIV) prevalence. In the
context of increasingly constrained resources, mathe-
matical modelling can augment understanding and
support policy for implementing those strategies that
are most likely to bring public health and economic
benefits. In this paper, we present an overview of past
and recent contributions of TB modelling in this key
area, and suggest a way forward through a modelling
research agenda that supports a more effective response
to the TB-HIVepidemic, based on expert discussions at a
meeting convened by the TB Modelling and Analysis
Consortium. The research agenda identified high-
priority areas for future modelling efforts, including 1)
the difficult diagnosis and high mortality of TB-HIV; 2)
the high risk of disease progression; 3) TB health systems
in high HIV prevalence settings; 4) uncertainty in the
natural progression of TB-HIV; and 5) combined
interventions for TB-HIV. Efficient and rapid progress
towards completion of this modelling agenda will
require co-ordination between the modelling community
and key stakeholders, including advocates, health policy
makers, donors and national or regional finance
officials. A continuing dialogue will ensure that new
results are effectively communicated and new policy-
relevant questions are addressed swiftly.
K E Y WORD S : tuberculosis; mathematical modelling;
HIV; sub-Saharan Africa; systematic literature review
WHILE MYCOBACTERIUM TUBERCULOSIS
and the human immunodeficiency virus (HIV) are
independently responsible for substantial human
suffering and death, in areas where these pathogens
dually infect the population, their combined effect
has been devastating. HIV-related immunosuppres-
sion markedly increases the risk for progression to
tuberculosis (TB) disease after M. tuberculosis
infection,1 and may increase the risk of initial
infection; accordingly, in areas of generalised HIV
epidemics, there have been steep increases in TB
incidence.2 During periods of limited success in HIV
prevention and control, standard approaches for TB
control have been inadequate in these settings; novel
strategies are therefore urgently needed.3
Mathematical models, defined by Garnet et al. as
mechanistic representations for how disease burden is
established, are useful tools for projecting the
potential public health and economic impact of
interventions when population-level empirical data,
such as from cluster-randomised trials, are unavail-
able and too expensive, too time consuming or
unethical to acquire.4 Models can also provide insight
by simplifying complex systems into frameworks that
are more easily understood. For example, the
relationship between the scale-up of antiretroviral
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therapy (ART) and the subsequent impact on
population-level TB incidence is difficult to predict,
but can be understood using a combined model of
HIV and TB transmission.5 In a time of limited
resources, mathematical modelling, grounded in
available data, can be an important guide for the
rational use of resources in TB control, development
pipelines of new drugs, vaccines or diagnostics, and
highlight what empirical data gaps need to be filled.
Recognising the urgency of TB control in high HIV
prevalence settings and the potential contributions of
modelling, the TB Modelling and Analysis Consor-
tium (TB MAC, Table 1) convened its first meeting
between empirical scientists, policy makers and
mathematical modellers in September 2012 in Jo-
hannesburg, South Africa. The aim of this meeting
was to identify a modelling research agenda to
advance TB control in high HIV prevalence settings.
In the present perspective, we summarise the key
historical contributions of TB-HIV modelling follow-
ing a systematic literature review and identify a future
modelling research agenda that would help hasten the
reduction of the TB-HIV epidemic.
METHODS
A detailed report of the meeting preparations,
resources and documents available to the participants
and discussion outcomes can be found on the TB
MAC website (www.tb-mac.org/WorkAreas/
WorkArea/1). In summary, to identify existing TB
modelling and cost-effectiveness studies in high HIV
prevalence settings (restricted for this review to sub-
Saharan Africa or sub-populations with an adult HIV
prevalence of over 5%), a systematic literature review
was performed in September 2012. We searched
PubMed, private libraries, existing reviews and
mathematical modelling journals. Further details of
the review methods and results are given in the
Appendix, including details of the selection process in
Figure A.* A formal assessment of model quality was
considered to be beyond the scope of this review.
Existing research priority agendas were also scanned
for potential modelling questions (RMGJH and
RGW) to stimulate discussions.6–8
The above documents were used as preparatory
material for participants in a 2-day meeting in
Johannesburg, South Africa, in September 2012
between key stakeholders. Participants, including
empirical scientists, policy makers and mathematical
modellers, to discuss modelling research questions in
three main areas chosen to cover the breadth of TB
care and control: 1) screening and treatment of active
TB and latent tuberculous infection (LTBI), 2) TB
vaccines and immunology and 3) the economics of
TB. Discussions during the meeting focused primarily
on the potential opportunities for modelling efforts to
hasten the reduction of the TB-HIV epidemic. On
behalf of the meeting participants these lists of
research questions were consolidated into key themes
for TB care and control, which are described below.
KEY CONTRIBUTIONS OF TB MODELLING IN
HIGH HIV PREVALENCE SETTINGS
The review identified 69 papers. A brief summary of
these papers and a selection process flow chart can be
found in the Appendix. Despite its public health
relevance, modelling activity in TB was limited before
2005, after which six or more papers were published
each year. Strikingly, nearly all TB-HIV models
started from the perspective of the natural history of
TB, adding a simple layer on HIV to the core
structure on TB,9 although there are notable excep-
tions to this trend.10
Natural history of TB in high HIV prevalence setting
In February 1992, Schulzer et al. published the first
model to quantify the consequences of the emerging
disastrous association between HIV and TB.9 Later
confirmed by others, these models predicted the steep
rise in TB incidence that was to overwhelm many TB
programmes in these, usually low-income, set-
tings.2,11–15
Antiretroviral therapy and isoniazid preventive therapy
In 2003, Williams and Dye used modelling to show
how the expansion of access to ART in high HIV
prevalence settings would contribute little to control-
ling TB incidence in the population, unless ART was
started early (e.g., at CD4 levels of 500/ll), with very
high (85%) effective coverage.10
A large number (n ¼ 17) of the modelling papers
incorporated preventive therapy, usually isoniazid
preventive therapy (IPT). However, the evaluation
showed that assumptions on key parameters such as
the level and duration of protection offered by IPT
varied widely, complicating the interpretation of
these generally positive results. Models assumed
between a 34%16 or 100%17 reduction in the risk
of TB during IPT, while the assumed duration of
protection post-therapy varied between immediate
loss of effect18 to lifelong protection.17
Impact of additional interventions for TB-HIV
Mathematical models of TB-HIV have also been used
to explore enhancements to DOTS-based pro-
grammes, including active case finding19 and expand-
ing access to culture-based diagnosis or drug
susceptibility testing.20 These models usually found
that such enhancements could provide substantial
benefits. In 2010, the World Health Organization
* The Appendix is available in the online version of this article,
at http://www.ingentaconnect.com/content/iuatld/ijtld/2014/
00000018/00000005/art00004
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endorsed a new TB diagnostic test, XpertwMTB/RIF
(Cepheid, Sunnyvale, CA, USA), generating a need
for models that explored costs benefits as well as
operational aspects of integrating these novel devices
into existing TB care and control infrastructure.
While four papers in this review explored the
individual benefits and costs,21 none incorporated
the population effect of improved diagnosis through a
transmission component (note: one paper has since
addressed this22).
Implementations of interventions for TB
Models can also inform policy questions on imple-
mentation of new interventions and tools. Often such
models will include an operational modelling com-
ponent that explicitly captures key parts of the health
system.23 While the importance of the operational
modelling of combined TB-HIV interventions was
recognised, little work has been done in this area,
with only one paper addressing this issue, which
evaluated the impact of a novel diagnostic tool.23
A RESEARCH AGENDA FOR MODELLING OF TB
CONTROL IN HIGH HIV PREVALENCE SETTINGS
In the following sections, we identify five broad
priority areas for TB modelling research for the
support for TB care and control in high HIV
prevalence settings, discuss the empirical evidence
and suggest potential opportunities for future mod-
elling efforts. Specific research questions in each area
can be found in Table 2.
Priority area 1: diagnosis and mortality of TB-HIV
Among people living with HIV (PLHIV), TB is both
more difficult to diagnose than in HIV-negative
individuals and a major cause of death if untreated.2
To reduce mortality, early diagnosis and the resulting
access to lifesaving treatment for TB and often HIV, is
key. It is therefore likely that intensified case-finding
strategies (which aim to diagnose individuals at
earlier stages of disease)24 and improved diagnosis20
might have a disproportionate morbidity and mor-
tality benefit among HIV-positive individuals with
active TB disease. However, given the likely much
shorter duration of overall TB disease and higher
probability of smear-negative (i.e., presumably less
infectious) disease,2 the impact of such strategies on
M. tuberculosis transmission and future TB disease
incidence may be less pronounced.
Although the population-level benefits of intensi-
fied TB case finding and improved TB diagnosis
among PLHIV have not been conclusively demon-
strated,24 models can use the best available data to
help identify the approaches to diagnosis and case-
finding that are likely to be most cost-effective if
scaled up at the population level. For example,
models that incorporate routes of care-seeking and
diagnosis among individuals with HIV and TB can
augment these findings by relating them to existing
systems of care. Progress in this area is therefore
clearly dependent on increasing the empirical evi-
dence base related to the organisation of health
systems for HIV and TB in resource-constrained
settings (Priority area 3) as well as the progression
(Priority area 2) and pathogenesis (Priority area 4) of
TB-HIV.
Priority area 2: high risk of progression to active TB-HIV
HIV dramatically increases both the rate of TB
infection progressing to disease (as measured by
recurrent TB episodes with novel molecular finger-
prints),25 and the rate of progression from LTBI (as
measured by a positive tuberculin skin test) to active
TB disease.26 Thus, the potential role of preventing
progression (e.g., by using IPT or other preventive
therapy regimens, ART or post-exposure vaccines)
may be especially pronounced among this popula-
tion. While IPT has been demonstrated to reduce the
risk of active TB during treatment,27 there is ongoing
uncertainty about the duration of protection among
PLHIV after therapy completion.28 Recent modelling
studies have suggested that the failure of isoniazid to
sterilise is at least part of the explanation,29 although
Table 1 The TB Modelling and Analysis Consortium
The TB Modelling and Analysis Consortium (TB MAC, www.tb-mac.org), formed in June 2012, aims to improve global TB control by
coordinating and promoting mathematical modelling and other quantitative research activities to provide scientific support for policy
decisions and implementation. Its objectives are to:
1. Identify research questions concerning TB control that require input from mathematical modelling or other quantitative research
2. Facilitate sharing of data, information and expertise to achieve consensus on current knowledge and knowledge gaps, methodological
standards and current best practice for TB control decision making
3. Fund small analytical /modelling research projects
4. Disseminate results and tools to key stakeholders including TB control programmes and donors
To date TB MAC has held three meetings on high-priority issues: the first meeting was on the focus of this paper, TB control in high HIV
prevalence settings, which was held in Johannesburg, South Africa, in September 2012; the second was on the impact and cost-
effectiveness of current and future diagnostics for TB, which was held in Amsterdam, The Netherlands, in April 2013; and the third was on
the rational introduction of new drugs and drug regimens, which was held in Beijing, China, in September 2013. TB MAC will hold four
more meetings over 2014 and 2015. See www.tb-mac.org for full details, meeting reports and other resources useful for TB modellers
including this TB-HIV literature review (www.tb-mac.org/resources)
TB¼ tuberculosis; HIV¼ human immunodeficiency virus.
TB modelling for HIV-endemic countries 511
this may improve following immune recovery with
ART co-therapy.30
The population-level effects of TB preventive
interventions remain unclear. While models of the
impact of preventive therapy among PLHIV should
reflect this uncertainty, their guidance is needed to
inform decisions regarding the scale-up of preventive
therapy.
Advances in diagnostic tools to identify those
individuals at highest likelihood for progression,
coupled with better understanding of latency and
partial immunity in TB-HIV (Priority area 4), can
help to better inform the structure and parameter-
isation of these models. Earlier economic work on the
potential cost-effectiveness and cost savings from
preventive therapies will need to be revisited to
incorporate updated understanding about the dura-
tion of effectiveness, individual level effects and costs
of maintaining adherence to treatment.
Priority area 3: TB health systems in high HIV
prevalence settings
TB requires intensive, often directly observed, thera-
py with a short course of inexpensive drugs, whereas
HIV requires lifelong, mostly unsupervised treatment
with expensive agents and regular therapeutic mon-
itoring. However, in HIV-endemic regions, the
patients taking these drugs are often the same, and
synergistic efforts at linkage to TB and HIV care can
improve systems of diagnosis and treatment at
relatively low cost.31
Health systems in these settings must therefore
adapt to this reality. Operational and economic
models have great potential to inform decisions about
how to structure health systems, in particular to
inform the optimal level of service integration. Such
models can identify ways to resolve both allocative
inefficiencies (e.g., by combining resources in optimal
ways to provide services for those who are co-
infected) and technical inefficiencies (e.g., by com-
bining services in optimal ways to improve out-
comes). They can also assist in understanding the
delays and costs that service users face, and how to
reduce them.
Combined health system and economic models
could also help identify the corresponding health
systems investments needed to support the efficient
operation of both TB and HIV services. To date, such
health system models have been underutilised;23
however, as resources for TB and HIV care become
increasingly constrained, and new technologies con-
tinue to be scaled up, health systems models will
become increasingly important in helping to maxi-
mise value for money.
Priority area 4: uncertainty in the natural history of TB-
HIV
All epidemiological models of infectious diseases are
limited by the current state of knowledge of the
natural history of the pathogen. In the case of TB-
HIV, we must consider not only two individual
natural histories, but also the interaction of these
two (potentially) chronic infectious diseases. The
need for a more thorough understanding of the
natural history of TB-HIV is clear.
The natural history of untreated HIV is well-
known from cohort studies of HIV-infected individ-
uals before the availability of ART, and some insight
Table 2 Key TB-HIV modelling priority areas and sub-questions
1 Difficult diagnosis and high mortality of TB-HIV
 What is the most (cost-) effective case finding strategy?
 Can a simple algorithm be defined to guide optimal case-finding approaches for national programme staff and policy makers based on
epidemiological data on ARI, case notification proportion and HIV prevalence?
 What is the impact of reducing initial default and improving cure rates?
 What is the (cost-) effectiveness of new point-of-care diagnostic tests and algorithms?
 What might the contribution of novel therapeutic vaccines be?
2 High risk of disease progression to active TB-HIV
 Can models help us understand the degree and duration of protection from (isoniazid) preventive therapy among PLHIV in different
settings?
 What might the contribution of novel post-exposure vaccines in various target groups be?
3 TB health systems in high HIV prevalence settings
 How do operational processes influence the cost-effectiveness of TB control interventions in high HIV prevalence settings?
 What is the efficiency of TB-HIV services, and how can we improve value for money?
4 Uncertainty in the natural progression of TB-HIV
 Can models be used to quantify uncertainties in the natural history of Mycobacterium tuberculosis that are relevant for decision making,
and make recommendations for how to prioritise data collection activities?
 Would a highly simplified, user-friendly model for TB still be useful for policy makers?
 Can we use models to define proxy measure of intervention impact?
 Should we do a formal model comparison on the proportion of TB due to recent infection in relation to the estimated ARI?
 What are the resource requirements to scale up TB control interventions in high HIV prevalence settings?
5 Combined interventions to control TB-HIV
 Can a more complex model better estimate the impact of a range of combination TB prevention strategies?
 What is the most cost-effective combination of existing TB control interventions in high HIV prevalence settings?
 What might the contribution of novel pre/post-therapeutic vaccines be?
TB¼ tuberculosis; HIV¼ human immunodeficiency virus; ARI¼ annual risk of tuberculous infection; PLHIV¼ people living with HIV.
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exists into the natural history of TB from the pre-
chemotherapy era (1950s). However, the availability
of TB chemotherapy throughout the HIV era has
meant that, for ethical and methodological reasons,
studies to acquire this information in HIV-positive TB
patients are not possible – including the infectious
duration of untreated TB32 (and its relationship to
CD4 count and/or ART), TB mortality risk,33 and the
risk of re-infection and progression to disease relative
to non-HIV-infected individuals (Priority area 2).
To accurately project the impact of interventions
for TB in HIV-endemic regions, it is essential to
better understand these elements of natural history.
For example, the impact of early diagnosis cannot be
accurately estimated without knowing the duration
of infectiousness likely to be averted. Empirical
studies that provide further insight into these areas
are urgently needed; in the interim, models using
existing data may be able to better define and
communicate the bounds of our uncertainty.
Priority area 5: combined interventions to control TB-
HIV
If we are ultimately to achieve aggressive targets for
TB control in HIV-endemic regions, it is unlikely that
we can rely on a single intervention.34 Strategies for
the control of complex epidemics such as HIVand TB
will include multiple interventions for the foreseeable
future. As such, we must deploy a combination of
interventions that are intelligently targeted at differ-
ent steps of the M. tuberculosis transmission cycle.
Given the growing number of potential interven-
tions for the control of TB-HIV, including alternative
screening and diagnostic approaches (Priority area
1), preventive strategies (Priority area 2) and
alternative models for integrated care (Priority area
3), there is an opportunity for models to help
identify which interventions will likely perform best
when combined. For example, a combination of
preventive treatment (targeting LTBI) and intensified
case finding (i.e., targeting active disease) may be
more effective than one of intensified case finding
plus better passive diagnosis (i.e., both targeting
active disease).35 Economic considerations are also
critical, as certain interventions may be more
efficient to combine than others,36 as both provider
and patient costs are reduced through economies of
scope.
To be able to provide such insight, new models
with flexible structures capable of simulating the
impact and cost-effectiveness of relevant combina-
tions of interventions are urgently required. Such
models could provide a platform for comparing
alternative combinations of existing and novel
interventions that go beyond current policy in terms
of both impact and resource requirements, thus
helping to chart the fastest, most cost-effective course
possible for the elimination of TB in settings of high
HIV prevalence.
CONCLUSION
In this paper, we have identified five critical areas in
which TB-HIV models can help advance TB control
in high HIV prevalence settings. These include
questions ranging from improved understanding of
the natural history of TB-HIV to comparative impact
and cost-effectiveness achievable from implementa-
tion and combination of TB-HIV control strategies.
However, efficient and rapid progress towards the
completion of this modelling agenda will require co-
ordination between the modelling community and
key stakeholders, including advocates, health policy
makers, donors and national or regional finance
officials. They will be faced with decisions that will
increasingly reflect not simple, idealised comparisons
of individual interventions, but rather a complex
assessment of the optimal combination of available
options in real-world settings. As such, effective
models will incorporate operational components
and inform the prioritisation, sequencing and expect-
ed consequences of combination approaches that
involve both scaling up new techniques and improv-
ing existing systems.
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APPENDIX
Full search query for systematic literature review
We carried out a systematic literature review to
identify existing tuberculosis (TB) modelling and
cost-effectiveness studies in high human immunode-
ficiency virus (HIV) prevalence settings, with the aim
of highlighting gaps in existing work against current
research priorities and give an overview of the
modelling methods used to date.
We searched the medical literature using a PubMed
query which identified papers from an earlier
narrative review in 2008.1 The following search
query was used in September 2012: (tuberculosis OR
TB) AND ((mathem* AND (model OR models)) OR
(mathem* modell*) OR (mathem* modeling) OR
(modeling OR modelling) OR ‘Population dynam-
ics’[MeSH Terms] OR ‘Population dynamics’ OR
‘System dynamics’ OR ‘Computer simulation’ OR
‘Computer simulation’[MeSH Terms]).
We searched mathematical modelling journals for
any papers on TB (search for ‘tuberculosis’ OR ‘TB’)
and scanned references from existing reviews for
relevant papers. We also searched the personal
libraries of TB MAC steering committee members
(RGW, CD, AV, TC and DD) who kindly made their
personal libraries available. To identify those relevant
for high HIV prevalence settings, we included those
papers that included any of the terms ‘HIV’, ‘AIDS’,
‘human imm* or ‘Africa’ in their title, keywords or
abstract.
Papers were eligible for full-text review if they
were written in English and described a mathemat-
ical model of TB. For the purposes of this review, in
defining ‘mathematical model’, we followed Garnett
et al.2 and included decision analytic, cohort,
transmission, operational or within-host models,
but excluded purely statistical models and studies
using models to estimate only resource require-
ments. Papers were also excluded if they did not
model or use data from populations with high HIV
prevalence (restricted to sub-Saharan Africa or sub-
populations with an adult HIV prevalence of over
5%). Details of the selection process are given in
the Figure.3
Paper selection was done by RMGJH; data
extraction was done by RMGJH with support from
RGW.
Figure A Systematic review flow chart for selection of papers. HIV¼ human immunodeficiency virus; TB¼ tuberculosis.3 Note: File
with references can be downloaded at http://www.tb-mac.org/resources.
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Table A Summary of studies identified in the systematic review
Reference Year
First
author Primary research question
Main modelling
method used
Area of
contribution*
4 1992 Bermejo What is the impact of HIV on TB incidence in developing
countries?
Other (static
algebraic)
1
5 1992 Schulzer What will be the impact of the HIV epidemic on future TB rates
in sub-Saharan Africa?
† 1
6 1993 Heymann What is the impact of preventive and curative regimens on TB in
Africa?
† 2
7 1993 Massad How do HIV and TB interact in homogeneously mixing
populations?
† 1
8 1994 Dolin What is the global TB incidence and mortality between 1990
and 2000?
Other 1
9 1994 Schulzer How does a generalised HIV epidemic accelerate the rise of TB
incidence?
† 1
10 1995 Masobe What are the costs and benefits of providing IPT to a HIV-
positive population?
‡ 2
11 1997 Foster What are the costs and benefits of providing IPT to HIV-positive
individuals in Zambia?
§ 2
12 1998 Dye What is the impact of DOTS on global TB control? † 3
13 1999 Bell What is the cost-effectiveness of IPT in sub-Saharan Africa? ‡ 2
14 1999 Kirschner What are the within-host interaction dynamics of M.
tuberculosis and HIV?
¶ 1
15 2001 Porco What is the amplification impact of the HIV epidemic on TB
outbreaks?
† 1
16 2001 Wilton What is the cost-effectiveness of DOTS vs. non-DOTS treatment
to reduce the spread of MDR-TB?
§ 3
17 2002 Murray What are the social, demographic and clinical determinants of
cluster distribution?
‡ 1
18 2002 Raimundo What is the accelerating impact of HIV infection on TB incidence
in a closed population?
† 1
19 2003 Corbett What is the relationship between HIV prevalence and TB
incidence and mortality in a population?
Other (static
algebraic)
1
20 2003 Currie What are the relative benefits of treating active TB vs. TB and
HIV prevention in high HIV prevalence countries?
† 2
21 2003 Williams What is the potential population-level impact of ART on TB
incidence?
‡ 2
22 2004 Guwatudde What is the potential impact of IPT on TB in sub-Saharan Africa? † 2
23 2005 Baltussen What are the costs and health benefits of TB control in Africa
and South East Asia?
§ 3
24 2005 Currie What are the costs and benefits of seven TB control strategies in
high HIV prevalence countries?
§ 3
25 2005 Naresh What are the dynamics of HIV and TB co-infection in a variable
size population?
† 1
26 2006 Bachmann What is impact of IPT vs. ART on progression to TB disease in
HIV-positive individuals?
§ 2
27 2006 Cohen What is the potential contribution of IPT to the emergence of
drug-resistant TB?
† 2
28 2006 Dowdy What is the impact of enhanced diagnostics on TB in a high HIV
prevalence setting?
† 3
29 2006 Hughes How well can an individual-based model predict a TB epidemic
in a high HIV prevalence country?
† 1
30 2006 Jacquet What are the costs and benefits of expanding DOTS in Haiti? § 3
31 2006 Magombedze How do cytotoxic lymphocytes and the immune system
determine whether an infection progresses to TB disease?
¶ 1
32 2006 Shrestha What are the costs and benefits of TST screening before
initiating IPT in HIV-positive individuals in Uganda?
§ 2
33 2007 Basu What was the potential of control measures to reduce
nosocomial transmission of XDR-TB in Tugela Ferry?
† 3
34 2007 Shrestha What are the costs and benefits of an IPT programme in HIV-
positive individuals in Uganda?
§ 2
1 2008 Bacaer What is the impact of control measures on TB disease in South
African Township?
† 2
35 2008 Basu How could cross-strain immunity affect the spread of DR-TB? † 1
36 2008 Dowdy What is the impact of expanded culture and drug susceptibility
testing on TB mortality and incidence?
† 3
37 2008 Dowdy What are the potential costs and benefits of a point-of-care TB
diagnostic test in South Africa, Brazil and Kenya?
§ 3
38 2008 Escombe What is the relative infectiousness of MDR-TB in HIV-positive
individuals?
† 1
39 2008 Magombedze What are the immune mechanisms involved in M. tuberculosis
HIV co-infections?
¶ 1
40 2008 Millen What are the main factors that contribute to the overall delay in
diagnosis of TB?
§ 1
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Table (continued)
Reference Year
First
author Primary research question
Main modelling
method used
Area of
contribution*
41 2008 Sanchez What is the impact of reduced treatment duration and
enhanced case detection and cure on TB incidence and
mortality in populations with generalised HIV epidemics?
† 3
42 2008 Sharomi What are the synergistic interactions between HIV and M.
tuberculosis in a population?
† 1
43 2008 Wilkins What are the population pharmacokinetics of rifampicin in
pulmonary TB patients in South Africa?
¶ 1
44 2009 Basu How can epidemics of XDR-TB be averted in South Africa? † 3
45 2009 Basu What factors impact on the evolution of M. tuberculosis strain
virulence?
† 1
46 2009 Basu What are the benefits and risks of various IPT strategies in HIV
clinics?
† 2
47 2009 Bhunu What are the mathematical properties of an M. tuberculosis-HIV
co-infection model that includes ART?
† 2
48 2009 Dowdy Can short-term 5–10% annual declines in TB incidence be
sustained by high case detection alone?
† 3
49 2009 Laxminarayan Do the economic benefits of the Global Plan to Stop TB (2006–
2015) exceed the costs?
§ 3
50 2009 Naresh What is the effect of TB on the spread of HIV infection in a
logistically growing population?
† 1
51 2009 Roeger What are the mathematical properties of a combined TB-HIV
population model?
† 1
52 2009 Sanchez What factors can explain the rise in TB incidence in Kenya, given
the declining HIV trends?
† 1
53 2010 Bonnet What is the cost-effectiveness of direct vs. bleach sedimentation
smear microscopy?
§ 3
54 2010 Williams What is the potential population-level impact of ART on TB
incidence in nine African countries?
† 2
55 2010 Wood What are the driving factors behind the high ARI in children in a
South African community?
† 1
56 2011 Basu What interventions can interruptM. tuberculosis transmission in
institutional settings?
† 3
57 2011 Dodd What factors influence the performance and cost-effectiveness
of TB active case finding?
† 3
58 2011 Lin How can an operational model support a rational choice of TB
diagnostic strategy?
† 4
59 2011 Mellor Does incorporating household structure in a discrete event
simulation model of TB and HIV allow a comparison of
contact tracing and active case finding in high-risk groups?
‡ 3
60 2011 Mills How do contact patterns affect the population-wide impact of
IPT?
† 2
61 2011 Pretorius What are the statistical properties of TB episodes in a small
South African community?
† 1
62 2011 Samandari What is the cost-effectiveness of adding a CXR to a symptom-
only screen before IPT?
§ 2
63 2011 Srivastava What is the impact of pharmacokinetic variability on MDR-TB
emergence in M. tuberculosis strains?
¶ 1
64 2011 Tseng What is the cost-effectiveness of a BCG replacement vaccine in
Zambia?
§ 3
65 2011 Uys What is the impact of background transmission rates on the
relationship between the case detection rate and the resulting
decline in ARI?
† 1
66 2011 Vassall What is the impact of introducing Xpert on the cost-
effectiveness of TB care?
§ 3
67 2012 Abimbola What is the cost-effectiveness of Xpert or culture-based
screening for TB in patients initiating ART?
§ 3
68 2012 Andrews What is the cost-effectiveness of smear, Xpert or culture-based
screening for TB in patients initiating ART?
§ 3
69 2012 Maheswaran What is the cost-effectiveness of intensified case finding and IPT
in HIV-positive individuals in sub-Saharan Africa?
§ 2
70 2012 Manabe What is the cost-effectiveness of 4HR vs. 6HE# for the
continuation phase in anti-tuberculosis treatment in Uganda?
§ 3
71 2012 Sergeev What is the impact of HIV on the dynamics of DR-TB? † 1
* Describes the main area where the TB modelling paper contributed to: 1¼ natural history of TB in high HIV prevalence setting; 2¼ART and IPT; 3¼ impact of
additional interventions for TB-HIV; 4¼ implementations of TB interventions.
† Compartmental population-based model with a dynamic transmission component, i.e., the risk of infection at a given time is dependent on the prevalent number
of infectious TB cases at that time.
‡ A population model without the dynamic transmission component.
§ Cost-effectiveness model using a decision tree (including Markov models) method.
¶ Usually a compartmental model that captures within-host processes of M. tuberculosis infection and TB disease.
# H¼ isoniazid; R¼ rifampicin; E¼ ethambutol. Numbers before the letters indicate the duration in months of the phase of treatment.
HIV ¼ human immunodeficiency virus; TB ¼ tuberculosis; IPT ¼ isoniazid preventive therapy; MDR-TB ¼ multidrug-resistant TB; ART ¼ antiretroviral therapy;
TST ¼ tuberculin skin test; XDR-TB ¼ extensively drug-resistant TB; DR-TB ¼ drug-resistant TB; ARI ¼ annual risk of infection; CXR ¼ chest X-ray; BCG ¼
bacille Calmette-Gue´rin; Xpert ¼ XpertW MTB/RIF.
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R E S UM E
Les approches existantes de la lutte contre la tuberculose
(TB) n’ont eu qu’un succe`s relatif dans les zones a`
pre´valence e´leve´e de virus de l’immunode´ficience
humaine (VIH). Dans un contexte de ressources de
plus en plus limite´es, un mode`le mathe´matique peut
augmenter la compre´hension et soutenir les politiques de
mise en œuvre de strate´gies plus susceptibles d’offrir des
be´ne´fices en termes d’e´conomie et de sante´ publique.
Dans cet article, nous pre´sentons un aperc¸u des
contributions passe´es et re´centes de la mode´lisation de
la TB dans ce domaine cle´ et sugge´rons une fac¸on de
re´pondre plus efficacement a` l’e´pide´mie de TB-VIH
graˆce a` un programme de recherche de mode´lisation en
se basant sur des discussions d’experts lors d’une re´union
convoque´e par le Consortium de mode´lisation et
d’analyse de la TB. Le programme de recherche a
identifie´ des domaines hautement prioritaires pour les
futures activite´s de mode´lisation, notamment : 1) les
difficulte´s de diagnostic et la mortalite´ e´leve´e de la TB-
VIH ; 2) le risque e´leve´ de progression de la maladie ;
3) le syste`me de prise en charge de la TB dans les zones a`
haute pre´valence du VIH ; 4) l’incertitude de la
progression naturelle de la TB-HIV ; et 5) les
interventions combine´es pour la TB-VIH. Une
progression efficace et rapide vers l’ache`vement de ce
programme de mode´lisation ne´cessitera une
coordination entre la communaute´ de mode´lisation et
les partenaires principaux, responsables de plaidoyer,
de´cideurs politiques, donateurs et responsables
financiers nationaux ou re´gionaux. Un dialogue
continu s’assurera que les nouveaux re´sultats sont
re´ellement diffuse´s et que les nouvelles questions
relatives aux politiques sont prises en compte
rapidement.
R E S UM E N
Los enfoques actuales de lucha contra la tuberculosis
(TB) solo han alcanzado una eficacia parcial en las zonas
con alta prevalencia de la infeccio´n por el virus de la
inmunodeficiencia humana (VIH). En el contexto de una
restriccio´n progresiva de los recursos, los modelos
matema´ticos pueden mejorar la comprensio´n y dar
mayor respaldo a las polı´ticas encaminadas a la
ejecucio´n de las estrategias con mayor probabilidad de
aportar beneficios de salud pu´blica y ventajas
econo´micas. En el presente artı´culo se examinan las
contribuciones pasadas y recientes de la modelizacio´n en
esta importante aspecto y se propone una forma de
avanzar, mediante un programa de investigacio´n en
modelizacio´n, que respalde una respuesta ma´s eficaz a la
epidemia de TB-VIH, a partir de los intercambios de los
expertos durante una reunio´n convocada por el
Consorcio de Modelizacio´n y Ana´lisis en TB. El
programa de investigacio´n encontro´ esferas de alta
prioridad para las futuras iniciativas de modelizacio´n,
como son: 1) el diagno´stico difı´cil y la alta mortalidad de
la coinfeccio´n por el TB-VIH; 2) el alto riesgo de
progresio´n hacia la enfermedad tuberculosa; 3) los
sistemas de atencio´n de la TB en los entornos con alta
prevalencia del VIH; 4) la incertidumbre sobre la
evolucio´n natural de la TB-VIH; y 5) las
intervenciones conjuntas en materia de TB-VIH. El
progreso eficaz y ra´pido hacia la culminacio´n de este
programa de modelizacio´n exigira´ una coordinacio´n
entre la comunidad de la modelizacio´n y los principales
interesados directos, entre ellos los promotores, los
responsables de elaborar las polı´ticas sanitarias, los
donantes y los funcionarios encargados de las cuestiones
financieras a escala nacional y regional. Un dia´logo
sostenido lograra´ la difusio´n eficaz de los resultados
recientes y el planteamiento oportuno de nuevos
aspectos relacionados con las polı´ticas.
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